Soligenix, Inc. is a US late-stage biopharmaceutical company that develops and sells products focused on treating rare diseases. The company operates two segments: Specialized Biotherapeutics, and Public Health Solutions. In Specialized Biotherapeutics, Soligenix develops SGX301 and SGX942, photodynamic and innate defense regulator therapies for inflammatory diseases, respectively. They also offer proprietary formulations of oral beclomethasone 17,21-dipropionate SGX203 and SGX302 that treats gastrointestinal and skin disorders. In Public Health Solutions, the company focuses on the manufacturing of vaccine candidates that treat infectious diseases like Ricin toxin, COVID-19, antibiotic-resistant diseases, and therapeutic candidates for thermostabilizing vaccines.